Archiv der Kategorie ‘Warner Chilcott‘

Generikahersteller Actavis kauft Warner Chilcott in Milliardendeal

Tuesday, den 21. May 2013

Milliardenuebernahme bahnt sich an Actavis zeigt Interesse an Warner Chilcott

Monday, den 13. May 2013

Will These Numbers from Warner Chilcott Be Good Enough for You?

Thursday, den 21. February 2013

Warner Chilcott buy – New Analyst Rating from Jefferies & Company Inc.

Tuesday, den 13. November 2012

Warner Chilcott buy – New Analyst Rating from UBS AG

Monday, den 10. September 2012

Warner Chilcott buy – New Analyst Rating from UBS AG

Friday, den 7. September 2012

Warner Chilcott (WCRX) Upgrade from Hold to Buy – Analyst rating from Needham

Thursday, den 9. August 2012

Warner Chilcott buy – New Analyst Rating from Needham & Company, LLC

Thursday, den 9. August 2012

Novartis verkauft US-Vertriebsrechte fuer "Enablex" an Warner Chilcott

Friday, den 24. September 2010

Warner Chilcott ( WCRX ) Initial Recommendation Outperform – Analyst rating from RBC Capital Mkts

Friday, den 23. July 2010

Warner Chilcott (WCRX) Upgrade from Hold to Buy – Analyst rating from Jefferies

Monday, den 17. May 2010

Warner Chilcott ( WCRX ) Upgrade from Hold to Buy($30) – Analyst rating from Jefferies

Monday, den 17. May 2010

Warner Chilcott (WCRX) Upgrade from Average to Buy – Analyst rating from Caris & Company

Friday, den 5. February 2010

Warner Chilcott (WCRX) Initial Recommendation – Outperform – Analyst rating from Oppenheimer

Wednesday, den 3. February 2010

Warner Chilcott (WCRX) Upgrade from Average to Buy – Analyst rating from Caris & Company

Tuesday, den 2. February 2010

Warner Chilcott (WCRX) Downgrade from Buy to Hold – Analyst rating from Jefferies & Co

Thursday, den 28. January 2010

Warner Chilcott ( WCRX ) Downgrade from Buy to Hold($26.5) – Analyst rating from Jefferies & Co

Thursday, den 28. January 2010

Warner Chilcott (WCRX) Downgrade from Buy to Average – Analyst rating from Caris & Company

Monday, den 25. January 2010

Warner Chilcott ( WCRX ) Downgrade from Buy to Average($30) – Analyst rating from Caris & Company

Monday, den 25. January 2010